Feb 19, 2020
InDex Pharmaceuticals' In-depth Analysis of the CONDUCT Study Confirms the Successful Top Line Results and Supports the Strategy Going Forward
Jun 26, 2019
InDex Pharmaceuticals Enrolls Last Patient in Phase IIb Study CONDUCT With Cobitolimod
Jun 05, 2019
US Gastroenterologists Report VARSITY Trial Data and JAK Inhibitor Safety Concerns Will Impact Their Prescribing Behavior in Ulcerative Colitis, with Potential Implications for Crohn's Treatment
May 16, 2019
Takeda to Highlight Compelling New Data and Portfolio Advances for Gastrointestinal (GI) Diseases at DDW 2019
May 16, 2019
4D Presents Phase Ib Clinical Data on Thetanix®
Mar 11, 2019
New Phase 3 STELARA® (ustekinumab) Data Show Positive Results As Maintenance Therapy In Adults With Moderate To Severe Ulcerative Colitis
Oct 05, 2018
Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease
Jun 03, 2018
Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease
Nov 21, 2017
Takeda's Entyvio Defends Share Against Janssen's Stelara in the Crohn's Disease Market, and Pressure in the Ulcerative Colitis Market May Heat Up in Early 2018 if Pfizer's Xeljanz Secures an FDA Win
Nov 09, 2017
New Post-Hoc Analysis Evaluating Deep Remission with Entyvio® (vedolizumab) in Patients with Moderately to Severely Active Ulcerative Colitis Recognized as "Poster of Distinction" at AIBD 2017 Annual Conference
Nov 02, 2017
US Market Report for Crohn's Disease Immunology Drugs 2018 - Unit Sales, ASPs, Market Value & Growth Trends
Nov 01, 2017
Meta-Analysis Using Real-World Data Evaluates Safety Profile of Entyvio® (vedolizumab) in Patients with Moderate to Severe Ulcerative Colitis or Crohn's Disease
Oct 16, 2017
New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio® (vedolizumab), Particularly in Biologic-Naïve Patients
Jun 21, 2017
InDex Pharmaceuticals Enrolls First Patient in the Phase IIb Study CONDUCT With Cobitolimod